| Characteristics | Patients who did not switch treatment (n = 305) | Patients who switched treatment (n = 202) | Total (n = 507) |
| Sex |
|
|
|
| Male | 138 (45.25%) | 95 (47.0%) | 233 (45.9%) |
| Female | 167 (54.75%) | 107 (53.0%) | 274 (54.1%) |
| Age Interval (years) |
|
|
|
| 18 - 25 | 93 (30.5%) | 34 (16.8%) | 127 (25.0%) |
| 26 - 35 | 123 (40.3%) | 69 (34.1%) | 192 (37.9%) |
| 36 - 45 | 59 (19.3%) | 49 (24.3%) | 108 (21.3%) |
| 46 - 55 | 24 (7.9%) | 38 (18.8%) | 62 (12.2%) |
| 56 - 65 | 5 (1.6%) | 11 (5.5%) | 16 (3.2%) |
| +65 | 1 (0.4%) | 1 (0.5%) | 2 (0.4%) |
| Average duration of Treatment | 12.9 ± 2.77 months | 21.43 ± 7.25 months | 16.30 ± 5.85 months |
| Treatment |
|
|
|
| TDF + 3TC + EFV | 211 (69.2%) | 19 (9.4%) | 230 (45.4%) |
| TDF + FTC + EFV | 69 (22.6%) | 5 (2.5%) | 74 (14.6%) |
| ZDV + 3TC + EFV | 13 (4.3%) | 0 | 13 (2.6%) |
| TDF + FTC + NVP | 4 (1.3%) | 55 (27.2%) | 59 (11.6%) |
| TDF + 3TC + NVP | 0 | 105 (52.0%) | 105 (20.7%) |
| d4T + 3TC + NVP | 8 (2.6%) | 18 (8.9%) | 26 (5.1%) |
| Previous Treatment |
|
|
|
| TDF + 3TC + EFV | -- | 34 (16.8%) | 34 (16.8%) |
| TDF + FTC + EFV | -- | 50 (24.7%) | 50 (24.7%) |
| ZDV + 3TC + EFV | -- | 112 (55.5%) | 112 (55.5%) |
| TDF + FTC + NVP | -- | 1 (0.5%) | 1 (0.5%) |
| TDF + 3TC + NVP | -- | 0 | 0 |
| d4T + 3TC + NVP | -- | 5 (2.5%) | 5 (2.5%) |